ProCE Banner Activity

Phase II TELESTO: Deferasirox vs Placebo in Patients With Low-/Intermediate-Risk Myelodysplastic Syndromes and Iron Overload

Slideset Download
Conference Coverage
Randomized study observed EFS benefit associated with deferasirox-based iron chelation therapy in lower-risk MDS.

Released: December 05, 2018

Expiration: December 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology